SCHEMBL5049103

SCHEMBL5049103

CSc1ccc(/C=C/c2nc(CCl)co2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 14/20 0.41
CYP1A1 P04798 4/20 0.41
CYP1A2 P05177 4/20 0.41
CYP1B1 Q16678 4/20 0.41
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
KMT2A Q03164 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5049104 1.00 ERBB2 (0.41) ERBB2CYP1A1CYP1A2CYP1B1KDM4E
SCHEMBL6579995 0.84 ERBB2 (0.55) ERBB2CYP1A2KDM4ENPC1MAPT
SCHEMBL6579991 0.84 ERBB2 (0.55) ERBB2CYP1A2KDM4ENPC1MAPT
SCHEMBL4607765 0.82 ERBB2 (0.46) ERBB2
SCHEMBL4607770 0.82 ERBB2 (0.46) ERBB2
SCHEMBL4504715 0.82 ERBB2 (0.44) ERBB2
SCHEMBL4056632 0.82 ERBB2 (0.56) ERBB2CYP1A2KMT2A
SCHEMBL4504713 0.82 ERBB2 (0.44) ERBB2
SCHEMBL4056631 0.82 ERBB2 (0.56) ERBB2CYP1A2KMT2A
SCHEMBL6586055 0.81 ERBB2 (0.42) ERBB2NPC1RAB9ACASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405231-B2 Anticancer agents; inhibitors of the HER-signaling pathway with decreased toxicity, better solubility and improved pharmacokinetic profile; e.g. 1-[4-(4-(2-[(E)-2-(4-Methanesulfinyl-phenyl)-vinyl]-oxazol-4-ylmethoxy)-phenyl)-butyl]-1H-[1,2,3]triazole HOFFMANN-LA ROCHE INC. (US) 2008-07-29 US disclosed
EP-1725551-A1 OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-11-29 EP disclosed
WO-2005095393-A1 OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed
US-20050203064-A1 Novel oxidized thioether derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203064-A1 Novel oxidized thioether derivatives SULT1E1, CYP4F3, GPX4 ERBB2 619/4885CYP1A1 43/4885CYP1A2 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.